Stay updated with breaking news from Gilead Sciences Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.
Workforces have been growing in many of Spokane’s top manufacturing companies in recent years, coinciding with plans to further grow this...
/PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation...
The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of
Schroder Investment Management Group raised its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 8.8% in the fourth quarter, Holdings Channel reports. The fund owned 1,646,589 shares of the biopharmaceutical company’s stock after buying an additional 132,679 shares during the period. Schroder Investment Management Group’s holdings in Gilead Sciences were worth $133,390,000 as […]